Insider Buying: Zura Bio Limited (NASDAQ:ZURA) EVP Purchases 3,195 Shares of Stock

Zura Bio Limited (NASDAQ:ZURA) EVP Kiran Nistala acquired 3,195 shares of Zura Bio stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average cost of $3.13 per share, with a total value of $10,000.35. Following the completion of the purchase, the executive vice president now owns 3,195 shares in the company, valued at approximately $10,000.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Zura Bio Stock Performance

ZURA stock opened at $4.41 on Friday. Zura Bio Limited has a twelve month low of $2.00 and a twelve month high of $14.00. The business has a fifty day moving average of $3.19 and a 200-day moving average of $4.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZURA. Raymond James & Associates raised its holdings in Zura Bio by 14.0% during the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after acquiring an additional 9,481 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Zura Bio in the 3rd quarter valued at $224,000. Forefront Analytics LLC bought a new position in shares of Zura Bio in the 3rd quarter valued at $95,000. Silverarc Capital Management LLC lifted its stake in shares of Zura Bio by 152.5% in the 3rd quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock valued at $2,667,000 after acquiring an additional 244,040 shares during the last quarter. Finally, Eisler Capital US LLC bought a new position in Zura Bio during the 3rd quarter worth $660,000. 61.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $16.00 price target (down from $17.00) on shares of Zura Bio in a research note on Monday, April 1st. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $16.40.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.